Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

Cited In for PubMed (Select 18358729)

1.

New strategies for targeting matrix metalloproteinases.

Fields GB.

Matrix Biol. 2015 May-Jul;44-46C:239-246. doi: 10.1016/j.matbio.2015.01.002. Epub 2015 Jan 14. Review.

2.

Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.

Spicer TP, Jiang J, Taylor AB, Choi JY, Hart PJ, Roush WR, Fields GB, Hodder PS, Minond D.

J Med Chem. 2014 Nov 26;57(22):9598-611. doi: 10.1021/jm501284e. Epub 2014 Nov 11.

PMID:
25330343
3.

SKI306X inhibition of glycosaminoglycan degradation in human cartilage involves down-regulation of cytokine-induced catabolic genes.

Choi CH, Kim TH, Sung YK, Choi CB, Na YI, Yoo H, Jun JB.

Korean J Intern Med. 2014 Sep;29(5):647-55. doi: 10.3904/kjim.2014.29.5.647. Epub 2014 Aug 28.

4.

Activity of ADAM17 (a disintegrin and metalloprotease 17) is regulated by its noncatalytic domains and secondary structure of its substrates.

Stawikowska R, Cudic M, Giulianotti M, Houghten RA, Fields GB, Minond D.

J Biol Chem. 2013 Aug 2;288(31):22871-9. doi: 10.1074/jbc.M113.462267. Epub 2013 Jun 18.

5.

The synthesis and application of Fmoc-Lys(5-Fam) building blocks.

Tokmina-Roszyk M, Tokmina-Roszyk D, Fields GB.

Biopolymers. 2013 Jul;100(4):347-55. doi: 10.1002/bip.22222.

6.

Discovery of novel inhibitors of a disintegrin and metalloprotease 17 (ADAM17) using glycosylated and non-glycosylated substrates.

Minond D, Cudic M, Bionda N, Giulianotti M, Maida L, Houghten RA, Fields GB.

J Biol Chem. 2012 Oct 19;287(43):36473-87. doi: 10.1074/jbc.M112.389114. Epub 2012 Aug 27.

7.

The history of matrix metalloproteinases: milestones, myths, and misperceptions.

Iyer RP, Patterson NL, Fields GB, Lindsey ML.

Am J Physiol Heart Circ Physiol. 2012 Oct 15;303(8):H919-30. doi: 10.1152/ajpheart.00577.2012. Epub 2012 Aug 17. Review.

8.

Identification of exosite-targeting inhibitors of anthrax lethal factor by high-throughput screening.

Bannwarth L, Goldberg AB, Chen C, Turk BE.

Chem Biol. 2012 Jul 27;19(7):875-82. doi: 10.1016/j.chembiol.2012.05.013.

9.

Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.

Roth J, Minond D, Darout E, Liu Q, Lauer J, Hodder P, Fields GB, Roush WR.

Bioorg Med Chem Lett. 2011 Dec 1;21(23):7180-4. doi: 10.1016/j.bmcl.2011.09.077. Epub 2011 Sep 22.

10.

Peptide from the C-terminal domain of tissue inhibitor of matrix metalloproteinases-2 (TIMP-2) inhibits membrane activation of matrix metalloproteinase-2 (MMP-2).

Xu X, Mikhailova M, Chen Z, Pal S, Robichaud TK, Lafer EM, Baber S, Steffensen B.

Matrix Biol. 2011 Sep;30(7-8):404-12. doi: 10.1016/j.matbio.2011.07.001. Epub 2011 Aug 4.

11.

Gelatin degradation assay reveals MMP-9 inhibitors and function of O-glycosylated domain.

Vandooren J, Geurts N, Martens E, Van den Steen PE, Jonghe SD, Herdewijn P, Opdenakker G.

World J Biol Chem. 2011 Jan 26;2(1):14-24. doi: 10.4331/wjbc.v2.i1.14.

12.

Synthesis and biological applications of collagen-model triple-helical peptides.

Fields GB.

Org Biomol Chem. 2010 Mar 21;8(6):1237-58. doi: 10.1039/b920670a. Epub 2010 Jan 20. Review.

13.

Analysis of flavonoid-based pharmacophores that inhibit aggrecanases (ADAMTS-4 and ADAMTS-5) and matrix metalloproteinases through the use of topologically constrained peptide substrates.

Cudic M, Burstein GD, Fields GB, Lauer-Fields J.

Chem Biol Drug Des. 2009 Nov;74(5):473-82. doi: 10.1111/j.1747-0285.2009.00885.x. Epub 2009 Sep 28.

14.

Identification of specific hemopexin-like domain residues that facilitate matrix metalloproteinase collagenolytic activity.

Lauer-Fields JL, Chalmers MJ, Busby SA, Minond D, Griffin PR, Fields GB.

J Biol Chem. 2009 Sep 4;284(36):24017-24. doi: 10.1074/jbc.M109.016873. Epub 2009 Jul 1.

15.

Using fluorogenic peptide substrates to assay matrix metalloproteinases.

Fields GB.

Methods Mol Biol. 2001;151:495-518. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk